Xenon Pharmaceuticals Inc. (XENE)
NASDAQ: XENE · Real-Time Price · USD
54.53
+0.27 (0.50%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Xenon Pharmaceuticals Stock Forecast
Stock Price Forecast
The 11 analysts with 12-month price forecasts for Xenon Pharmaceuticals stock have an average target of 68.55, with a low estimate of 47 and a high estimate of 97. The average target predicts an increase of 25.71% from the current stock price of 54.53.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 16, 2026.
Analyst Ratings
The average analyst rating for Xenon Pharmaceuticals stock from 11 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 3 | 4 | 3 |
| Buy | 6 | 6 | 6 | 7 | 8 | 8 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 10 | 12 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Maintains $64 → $63 | Buy | Maintains | $64 → $63 | +15.53% | Mar 16, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $49 → $68 | Buy | Maintains | $49 → $68 | +24.70% | Mar 10, 2026 |
| Wedbush | Wedbush | Buy Maintains $47 → $64 | Buy | Maintains | $47 → $64 | +17.37% | Mar 10, 2026 |
| Deutsche Bank | Deutsche Bank | Strong Buy Maintains $56 → $90 | Strong Buy | Maintains | $56 → $90 | +65.05% | Mar 10, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $53 → $74 | Strong Buy | Maintains | $53 → $74 | +35.71% | Mar 10, 2026 |
Financial Forecast
Revenue This Year
4.15M
from 7.50M
Decreased by -44.65%
Revenue Next Year
107.78M
from 4.15M
Increased by 2,496.48%
EPS This Year
-4.86
from -4.36
EPS Next Year
-4.71
from -4.86
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 26.3M | 441.5M | ||||||
| Avg | 4.2M | 107.8M | ||||||
| Low | n/a | 13.7M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 250.0% | 10,536.7% | ||||||
| Avg | -44.7% | 2,496.5% | ||||||
| Low | - | 230.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -4.68 | -0.58 | ||||||
| Avg | -4.86 | -4.71 | ||||||
| Low | -5.10 | -5.95 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.